These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21550231)

  • 21. [Pharmacoeconomics. Potent drugs, diseases are costly].
    Flaten O
    Tidsskr Nor Laegeforen; 1994 Apr; 114(11):1345-6. PubMed ID: 8079219
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pharmacoeconomics in contemporary medicine].
    Czech M
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():16-9. PubMed ID: 15524007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drugs take the spotlight in steering clinical, economic direction for ESRD.
    Neumann ME
    Nephrol News Issues; 2004 Jun; 18(7):50-1. PubMed ID: 15232997
    [No Abstract]   [Full Text] [Related]  

  • 24. Precipitating factors for pharmaceutical firms.
    McCarthy R
    State Health Care Am; 1997; ():39-43. PubMed ID: 10168083
    [No Abstract]   [Full Text] [Related]  

  • 25. Strategic planning for applied pharmacoeconomics programs.
    Wanke LA; Ryan GM
    Pharm Pract Manag Q; 1996 Jan; 15(4):64-74. PubMed ID: 10153846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medicine. The intangible value of vaccination.
    Rappuoli R; Miller HI; Falkow S
    Science; 2002 Aug; 297(5583):937-9. PubMed ID: 12169712
    [No Abstract]   [Full Text] [Related]  

  • 27. [Economical evaluation of drugs. A steering method for the pharmaceutical sector of the 1990's?].
    Grund J; Husbyn H
    Tidsskr Nor Laegeforen; 1994 Mar; 114(8):947-50. PubMed ID: 8191475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
    Zaric GS
    Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The power of pharmacoeconomics.
    Healthc Exec; 2000; 15(1):44-5. PubMed ID: 11067028
    [No Abstract]   [Full Text] [Related]  

  • 30. Toward a rational, value-based drug benefit for Medicare.
    Lopert R; Moon M
    Health Aff (Millwood); 2007; 26(6):1666-73. PubMed ID: 17978385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomics: the new dismal science.
    Luchins DJ
    Adm Policy Ment Health; 2004 May; 31(5):425-7. PubMed ID: 15379388
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmaceutical industry financial performance.
    Goodman M
    Nat Rev Drug Discov; 2009 Dec; 8(12):927-8. PubMed ID: 19949398
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-23. PubMed ID: 18345558
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
    Zaric GS; O'brien BJ
    Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
    [No Abstract]   [Full Text] [Related]  

  • 38. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacoeconomics in the era of individualized medicine.
    Waldman SA; Terzic A
    Clin Pharmacol Ther; 2008 Aug; 84(2):179-82. PubMed ID: 18679176
    [No Abstract]   [Full Text] [Related]  

  • 40. [Pharmacoeconomics and cost of cancer drugs].
    Camps Herrero C; Caballero Díaz C; Blasco Cordellat A
    Farm Hosp; 2010 Mar; 34 Suppl 1():12-5. PubMed ID: 20920852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.